Healthcare worker labels a sample | Representational image | Bloomberg
Healthcare worker labels a sample | Representational image | Bloomberg
Text Size:

New Delhi: A corticosteroid used to suppress skin allergies and treat rheumatic disorders has shown promise in the treatment of Covid and has succeeded to significantly reduce mortality risk.  

Corticosteroids are a class of hormones secreted by the adrenal gland. Drugs of this class are synthetic copies of these compounds.

The University of Oxford issued a statement Tuesday, highlighting the positive outcome of one arm of the ‘Recovery Trial’ — the dexamethasone arm.

ThePrint takes a look at the drug, its usual usage and the trial.

The drug

Dexamethasone is a corticosteroid commonly-used to reduce inflammatory conditions in the body such as allergic disorders and inflammatory bowel disease. It is also used to treat autoimmune disorders such as lupus, rheumatoid arthritis and myasthenia gravis.

While it reduces inflammation, and is a life-saving drug for patients of these diseases, it also tends to suppress the natural immunity of the body, which is why patients are often initiated into it only after they have been tested for opportunistic infections such as tuberculosis. 

The chances of the patient catching such an infection during the course of use of the drug are very high. Depression and elevation of blood pressure are among its side-effects.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.

SUBSCRIBE NOW


Also read: Remdesivir included as ‘investigational therapy’ for emergency Covid use: Health Ministry


The Recovery trial findings

The ‘Recovery Trial’ that is being carried out by Oxford scientists recruited over 11,500 patients in over 175 NHS (National Health Service) hospitals in the UK. The recruitment for the dexamethasone arm stopped on 8 June. 

According to the statement by the university: “A total of 2,104 patients were randomised to receive dexamethasone 6 mg once per day (either by mouth or by intravenous injection) for ten days and were compared with 4,321 patients randomised to usual care alone. Among the patients who received usual care alone, 28-day mortality was highest in those who required ventilation (41 per cent), intermediate in those patients who required oxygen only (25 per cent), and lowest among those who did not require any respiratory intervention (13 per cent).

“Dexamethasone reduced deaths by one-third in ventilated patients… and by one-fifth in other patients receiving oxygen only,” it stated.

Based on these results, one death would be prevented by treatment of around 8 ventilated patients or around 25 patients requiring oxygen alone. Overall dexamethasone reduced the 28-day mortality rate by 17 per cent, the statement added.

Peter Horby, professor of Emerging Infectious Diseases in the Nuffield Department of Medicine, University of Oxford, and one of the chief investigators for the trial, said: “Dexamethasone is the first drug to be shown to improve survival in Covid-19. This is an extremely welcome result. The survival benefit is clear and large in those patients, who are sick enough to require oxygen treatment. So dexamethasone should now become standard of care in these patients.”

“Dexamethasone is inexpensive, on the shelf, and can be used immediately to save lives worldwide,” Horby said.

Other arms of the trial

The ‘Recovery Trial’ is one of the biggest trials currently ongoing to look for therapeutic options against Covid-19. It started with six arms — Lopinavir-Ritonavir (commonly used second line drugs to treat HIV), Low-dose Dexamethasone, Hydroxychloroquine (this arm is now stopped), Azithromycin (a commonly used antibiotic), Tocilizumab (an anti-inflammatory treatment given by injection) and Convalescent plasma (collected from donors who have recovered from Covid and contains antibodies against the SARS-CoV-2 virus). 

The trial was in the news recently as the first to report after The Lancet retracted a study earlier this month, which said hydroxychloroquine does not have any efficacy in treatment of Covid. 

The Lancet study, retracted because of concerns about the quality of data used, had also reached similar conclusions. 

India continues to repose its faith in the drug for treatment and prevention of Covid even though the US FDA (Food and Drug Administration) has withdrawn its approval for emergency use of the drug in Covid patients. 

Hydroxychloroquine is also a part of the multi-country ‘Solidarity’ trial anchored by the World Health Organization.

The ‘Recovery Trial’ protocol does not exclude participants receiving other treatments for Covid. That is why in a recent note to investigators, the trial managers said patients who are receiving remdesivir, can also be a part of the trial as the drug, touted as one of the most promising therapeutic options against Covid, is not known to interact with any of the drugs being tried in the various arms.

The trial is supported by a grant to the University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR) and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and Melinda Gates Foundation, the Department for International Development, Health Data Research UK, the Medical Research Council Population Health Research Unit, and NIHR Clinical Trials Unit Support Funding.


Also read: Not just for flu but even BP and gynaecology — how telemedicine is filling a Covid vacuum


 

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

2 Comments Share Your Views

2 COMMENTS

  1. It is all TOOKE BAAZi trial and error . hit and miss, flying blindfold … some Baba Ayurveda may suggest cow urine or neem an dhaldi combination

  2. Dexamethasone is age old steroid drug which works as anti inflammatory through immuno modulation. The drug is a choice to treat hyper respnse of immune system and allergies. The drug is also used in COPD and Rheumatic arthritis. In the case of COVID treatment, it will be surely beneficial to deal with life threatening cytokine storm in the ARDS which leads to septic shock in critical patients. However, this drug should not be taken without prescription or indication of a certified medical practitioner because there are numerous reports pubished in journals that, since the drug is immuno modulator, treatment with dexamethasone during early stage of infection will effect increased viral load due to suppression of cell mediated immunity which may ultimately leading to delayed viral clearance from the body. I suggest this drug should be given only to the individuals who are under ARDS or advance SARI. I am worried since this drug is very cheap and readily available in medical shops, it may be misused with undesirable outcomes. I have written to PM portal too, but I afraid if give any attention to PMO officials.

LEAVE A REPLY

Please enter your comment!
Please enter your name here